TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
KLRS

Kalaris Therapeutics, Inc.

Healthcare · Biotechnology

2.00$ -4.7% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Kalaris Therapeutics, Inc. (KLRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 30.5% of the shares are freely tradable; institutional investors hold 77.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 77.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 8.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 30.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 24Mio.

Largest Shareholders

Institutions

Institutions KLRS
Name Stake (%) Shares Change (%) Date
Samsara BioCapital, LLC 54.11 12,881,175 -0.5 06/30/2026
RTW INVESTMENTS, LLC 5.46 1,300,000 +0.0 06/30/2026
Alyeska Investment Group, L.P. 2.41 572,687 +0.0 06/30/2026
Siren, L.L.C. 1.83 435,798 +0.0 06/30/2026
Vanguard Capital Management, LLC 1.67 398,712 +56.1 06/30/2026
Ikarian Capital, LLC 1.51 360,000 +0.0 06/30/2026
UBS Group AG 1.10 262,131 +4,138.9 06/30/2026
Renaissance Technologies Corp 0.63 149,351 +125.8 06/30/2026
Marshall Wace Asset Management Ltd 0.58 139,201 +105.1 06/30/2026

Funds

Funds KLRS
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.07 255,337 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?